Univeristy of Michigan neurologist, David Fink, MD, leads the team studying treatment for nerve damage related to diabetes and chemotherapy. They will join Diamyd Inc. in a project funded by the NIH to develop a new treatment for preventing nerve damage. “This is a case of ‘bench to bedside’ research,” Dr. Fink says. READ MORE …
U of M Earns $3 Million Grant to Develop Treatment for Nerve Damage Read More »
Diamyd Medical and the University of Michigan have been awarded a $3M three-year NIH grant to develop a product for use in preventing chemo-induced neuropathy. The product could be administered to cancer patients before they start chemotherapy treatments. READ MORE Source: Genetic Engineering & Biotechnology News
Dr. Bryan Schneider, MD, associate professor of medicine at Indiana University School of Medicine, was announced as the recipient of a $450,000 grant to further his research on the relationship between taxane-induced neuropathy and clinical outcomes with other chemotherapy treatments. About one-third of patients who receive chemotherapy with a taxane develop neuropathy. His research aims …
Cannabidiol – a compound derived from marijuana – may be a promising new treatment to prevent the development of painful neuropathy in patients receiving the chemotherapy drug paclitaxel. These results were published in Anesthesia & Analgesia based on animal experiments performed at Temple University School of Pharmacy, Philadelphia. READ MORE Source: Newswise
Colleen Erb, MSN, ACNP-BC, AOCNP, from Fox Chase Cancer Center writes about the debilitating effects of cancer treatments for patients – specifically peripheral neuropathy. Her article is in-depth and loaded with information. READ MORE Source: OncologyNurseAdvisor.com
In a program designed to facilitate the development and expedite the review of new drugs, the FDA created the Fast Track program. DARA BioSciences has been awarded the Fast Track designation for their KRN5500 investigational drug which will be used for the treatment of neuropathic pain in cancer patients. DARA earlier reported positive results from …
A new study has identified the first genetic biomarkers for taxane-induced peripheral neuropathy, a potentially severe complication of taxane chemotherapy. Dr. Bryan Schneider, lead author and a physician/researcher at the Indiana University Melvin and Bren Simon Cancer Center, said, “This may allow for better counseling, use of alternative drugs or schedules, or omission of taxane …
Genetic Biomarker Predicts Taxane-induced Neuropathy Read More »
The Institute of Cancer Research (ICR) has published a new study stating that a genetic test has been found that predicts whether bone marrow cancer treatments, including thalidomide, are likely to cause peripheral neuropathy. All common treatment regimes for multiple myeloma, an aggressive cancer that affects a type of white blood cell in the bone …
Genetic Test Could Predict When Myeloma Drugs Will Cause PN Read More »
Many treatments have been used to try and prevent Chemo-induced Peripheral Neuropathy (CIPN). And, clinical trials are needed so researchers can find out more about what helps. Cancer.org has information you can use about potential treatments and clinical trials. Â READ MORE Source: Cancer.org
Phase 2A Clinical Study shows Positive Results December 2010: DARA BioSciences reports additional positive results from its successfully completed study for the treatment of neuropathic pain in patients with cancer. Learn more about Phase 2A Clinical Study shows Positive Results Source: GlobeNewswire 13th World Congress on Pain October 2010: The results of a new study …
Chemo-Induced Peripheral Neuropathy: 2010 Archive Read More »
